You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,114,909

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,114,909 protect, and when does it expire?

Patent 8,114,909 protects HORIZANT and is included in one NDA.

This patent has twenty-two patent family members in fifteen countries.

Summary for Patent: 8,114,909
Title:Treating or preventing restless legs syndrome using prodrugs of GABA analogs
Abstract: Disclosed herein are methods of using prodrugs of gamma aminobutyric acid (GABA) analogs and pharmaceutical compositions thereof to treat or prevent restless legs syndrome in humans, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating or preventing restless legs syndrome.
Inventor(s): Barrett; Ronald W. (Saratoga, CA), Canafax; Daniel M. (Half Moon Bay, CA)
Assignee: XenoPort, Inc. (Santa Clara, CA)
Application Number:10/969,196
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,114,909

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-002 Dec 13, 2011 RX Yes No   Start Trial   Start Trial TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS   Start Trial
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-001 Apr 6, 2011 RX Yes Yes   Start Trial   Start Trial TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,114,909

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2004274002   Start Trial
Brazil PI0414481   Start Trial
Canada 2538802   Start Trial
China 1871021   Start Trial
European Patent Office 1677812   Start Trial
Israel 174282   Start Trial
Israel 200687   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.